Based on the potential for the immune stimulation to interfere with further dose escalation, Tekmira decided to conclude the trial...The trial is an open-label, dose-escalation study evaluating the safety and tolerability of TL32711 in adults with solid tumors or lymphoma refractory to standard therapies
The double-blind, placebo-controlled, dose escalation safety study in healthy subjects is being conducted at the St. Louis University Center for Vaccine Development
BioInvent International AB, of Lund, Sweden, treated the first patient in an open, dose-escalation Phase I study of the company's antibody BI-505 for patients with advanced multiple myeloma
The open-label, dose-escalation study will determine the safety, tolerability and pharmacokinetics of the drug...The trial is designed to determine safety and tolerability, starting with a dose-escalation phase
The dose-escalation study will investigate the drug in 30 to 60 patients with myelofibrosis and is designed to allow for preliminary assessment of the compound's activity, including its effect on spleen size, hematological symptoms, quality of life and markers of aberrant JAK2 activity in blood
Both clinical and preclinical programs were presented, including an update on its ongoing systemic Phase Ib/II trial of AVI-4658 showing that the compound was well tolerated by DMD patients in a dose escalation study that is now up to the sixth and final cohort (20 mg/kg...The safety profile of patients in the first cohort met pre-specified criteria for dose escalation and the second cohort has been opened for enrollment
EUSA Pharma Inc., of Doylestown, Pa., presented data showing that Prostascint (capromab pendetide), an FDA-approved monoclonal antibody targeting prostate-specific membrane antigen and linked to the radioisotope Indium-111, could be fused with CT imaging to guide dose escalation and predict disease-free survival
Ascenta Therapeutics Inc., of Malvern, Pa., reported results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in 16 patients with newly diagnosed glioblastoma multiforme, given either AT-101 administered concurrently with temozolomide and radiation therapy (Arm 1) or AT-101 as a component of temozolomide adjuvant therapy after chemoradiation (Arm 2...UCB SA, of Brussels, Belgium, reported new data from an open-label extension
Cytheris SA, of Paris, started a Phase I/IIa dose-escalation study in patients with idiopathic CD4 lymphocytopenia, an orphan disease characterized by abnormally low CD4 T-cell counts without evidence of HIV infection
Molecular Insight Pharmaceuticals Inc., of Cambridge, Mass., reported one-year follow-up data from a Phase I dose-escalation trial showing that Azedra demonstrated a positive safety profile and durable objective tumor responses in patients with neuroendocrine cancers, pheochromocytoma and paraganglioma
CytRx Corp., of Los Angeles, has begun a dose-escalation study with its oncology drug candidate tamibarotene combined with Trisenox (arsenic trioxide, Cephalon Inc.) in patients with relapsed acute promyelocytic leukemia
The multicenter, single-agent, open-label, accelerated dose escalation study will evaluate safety and determine the maximum tolerated dose and optimal dosing schedule of AT-406 in patients with advanced lymphomas and solid tumors
The primary objective of the open-label, single-agent dose escalation study is to evaluate the safety and tolerability of AR-12 by establishing the maximum tolerated dose
Oxygen Biotherapeutics Inc., of Durham, N.C., received approval to begin a Phase II, dose-escalation trial in Switzerland for use of Oxycyte in traumatic brain injury...The dose-escalation studies will focus on finding the lowest dose of Oxycyte that provides clinical benefit in traumatic brain injury while minimizing adverse effects
The dose escalation study is designed to evaluate the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of ascending single intravenous doses of PRM-151 in healthy subjects
Data from the randomized, double-blind, placebo-controlled, 135-patient, European, dose-escalation trial are expected in the first half of 2012